Difference between revisions of "Miinalainen IJ"
From Bioblast
Marte Verena (talk | contribs) |
|||
| Line 1: | Line 1: | ||
{{Person | {{Person | ||
|lastname=Miinalainen | |lastname=Miinalainen | ||
| | |firstname=Ilkka | ||
|address=NICB | |address=NICB | ||
| Line 10: | Line 9: | ||
Glasnevin, Dublin 9, Ireland | Glasnevin, Dublin 9, Ireland | ||
}} | }} | ||
{{Labelingperson}} | |||
Revision as of 15:35, 13 June 2013
| Name | Miinalainen Ilkka, |
|---|---|
| Institution | |
| Address | NICB
Centre for Bioanalytical Sciences (CBAS) Dublin City University Glasnevin, Dublin 9, Ireland, |
| City | |
| State/Province | |
| Country | |
| [email protected] | |
| Weblink | |
| O2k-Network Lab | IE Dublin Miinalainen I |
Labels:
Publications
| Published | Reference | |
|---|---|---|
| Raesaenen 2016 Proc Natl Acad Sci U S A | 2016 | Räsänen M, Degerman J, Nissinen TA, Miinalainen I, Kerkelä R, Siltanen A, Backman JT, Mervaala E, Hulmi JJ, Kivelä R, Alitalo K (2016) VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A 113:13144-49. |
